# Table of Contents

## Section I: General Information

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Updated by</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction to International Regulatory Affairs</td>
<td>Rajaram Balasubramanian, RAC, and Sharad Mi Shukla, RAC</td>
</tr>
<tr>
<td>2</td>
<td>Crisis Management for the Healthcare Product Industry</td>
<td>Treena Jackson, MS-QA/RA, MA, CQA, RAC, CSSGB</td>
</tr>
<tr>
<td>3</td>
<td>Clinical Trials, Good Clinical Practice, Regulations and Compliance</td>
<td>Anu Gaur, PhD, MBA, MSRA, RAC</td>
</tr>
<tr>
<td>4</td>
<td>In-Country Representation</td>
<td>Pei-Ting Chou, RAC, and Maria Connolly, MPH</td>
</tr>
<tr>
<td>5</td>
<td>International Advertising and Promotion</td>
<td>Treena Jackson, MS-QA/RA, MA, CQA, RAC, CSSGB</td>
</tr>
<tr>
<td>6</td>
<td>Compliance and Enforcement</td>
<td>Robert Rogers, MS, RAC</td>
</tr>
<tr>
<td>7</td>
<td>International Counterfeit Regulation</td>
<td>Viky Gilles Daniel Verna, MS, BME, MSPHarm, RAC (Global)</td>
</tr>
</tbody>
</table>

## Section II: Pharmaceuticals

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Updated by</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Premarket Requirements/Dossier Requirements</td>
<td>Monique Carter, MS, RAC, and Jesshanie Tabaniag</td>
</tr>
<tr>
<td>9</td>
<td>Authorization Procedures for Pharmaceutical Products</td>
<td>Orin Chisholm, GCULT, PhD, MTOPRA, and Monique Carter MS, RAC</td>
</tr>
<tr>
<td>10</td>
<td>Stability Test Requirements</td>
<td>Sharry Arora, MPHarm, and Rosie Dawes</td>
</tr>
<tr>
<td>11</td>
<td>Quality Systems and Inspectorate Process for Pharmaceuticals</td>
<td>Siegfried Schmitt, PhD, CSci, CCChem, FRSC</td>
</tr>
<tr>
<td>12</td>
<td>Generic Drug Products</td>
<td>Pallavi Trivedi, MPH, RAC, and Anu Gaur, PhD, MBA, MSRA, RAC</td>
</tr>
<tr>
<td>13</td>
<td>Over-the-Counter (OTC) Products</td>
<td>Robert Falcone, PhD</td>
</tr>
<tr>
<td>14</td>
<td>Pharmaceutical Postmarketing and Compliance</td>
<td>Valencia Hood-Humphrey, MSRA, and Kathrin Schalper, PhD, RAC</td>
</tr>
</tbody>
</table>
Section III: Medical Devices

Chapter 15 Medical Device Premarket Requirements .................................................................175
  Updated by Amina Abdal, MS, MBA

Chapter 16 Technical and Regulatory Requirements ..............................................................193
  Updated by Robin Stephens and Echo (Yuanyuan) Yu, MS, RAC

Chapter 17 Device Quality Systems .......................................................................................201
  Updated by Sharad Mi. Shukla, RAC, and Rajaram Balasubramanian, RAC

Chapter 18 In Vitro Diagnostic Medical Devices .................................................................211
  Updated by Gert Bos, PhD, FRAPS, and Jocelyn Jennings, MS, RAC

Chapter 19 Active Implantable Medical Devices .................................................................231
  By Gert Bos, PhD, FRAPS

Chapter 20 Software ..............................................................................................................241
  Updated by Echo (Yuanyuan) Yu, MS, RAC, and Raajdeep (Raaj) Venkatesan, MS (EE BME, MDDE), RAC

Chapter 21 Postmarket Requirements ...................................................................................253
  Updated by Pei-Ting S. Chou, RAC

Section IV: Biologics

Chapter 22 High-Risk Products: Products Derived from Biotechnology ...............................263
  Updated by Jocelyn Jennings, MS, RAC, and Angela L. Nelson, MBA, RAC

Chapter 23 Biosimilars: Basics and Recent Developments ....................................................279
  Updated by Pallavi Trivedi, MPH, RAC

Chapter 24 Vaccines .............................................................................................................311
  By Nicole Beard, MSc, PhD

Section V: Other Product Classifications

Chapter 25 Products Manufactured From Human Blood and Plasma ..................................329
  Updated by Indraneel Dasari, RAC

Chapter 26 Principles of Rare Diseases and Orphan Products Development .....................349
  Updated by Todd J. Banks, PharmD, RPh, Mridula Shukla, MS, RAC, and Phu Bo Chung, JD, MS, RAC

Chapter 27 Combination Products ......................................................................................359
  By Deanna Hughes, MS, RAC, and Beat U. Steffen, MSc, MBA

Chapter 28 Regulatory Considerations for Cell-Based Medicinal Products ......................371
  By Indraneel Dasari, RAC

Chapter 29 Food Supplements and Food for Special Medical Purposes .............................385
  By Irena Medarevic-Milobratovic, MPHarm, RAC

Chapter 30 Botanical Drug Products and Traditional Medicine .........................................399
  Updated by Irena Medarevic-Milobratovic, MPHarm, RAC, and Robert Falcone, PhD

Chapter 31 Global Pediatric Drug Development ..................................................................417
  By Lynne Georgopoulos, RN, MSHS, RAC, and Daniela Drago, PhD, RAC
Appendices
Comparative Matrix of Regulations Across Product Lines ..............................................................437
Glossary ........................................................................................................................................463
Index............................................................................................................................................479

Annexes
Annex 23-1. US Biosimilar Guidelines .........................................................................................283
Annex 23-2. Brazil Technical Guidelines, Coordination of Biological Products (CPBIH) and ANVISA ....285
Annex 23-3. EU Product-Specific Biosimilar Guidelines ..............................................................286

Figures
Figure 3-1. Acceptance of Foreign Clinical Data ............................................................................17
Figure 3-2. Quality Management System ....................................................................................21
Figure 6-1. The Inspection Process Related to Marketing Authorization Applications ......................52
Figure 6-2. GAP Guidelines Applicable to the Drug Lifecycle ......................................................53
Figure 7-1. An Example of the Common Logo Online Retailers of Medicines Must Displaya ............74
Figure 7-2. Flowchart Representing Product and Information Flow With Unique Product Identifiers and Accompanying Verification and Repository Systemsa ..................................................75
Figure 8-1. CTD Organization ......................................................................................................85
Figure 11-1. Drug Lifecycle Regulations ....................................................................................122
Figure 11-2. Assessors and Inspectors .......................................................................................123
Figure 11-3. EU Legal Instruments ............................................................................................124
Figure 11-4. Inspections as Part of the Drug Approval Process ..................................................125
Figure 14-1. MedDRA Coding Hierarchy ....................................................................................169
Figure 15-1. Decision Tree for Noninvasive Device Classification ..............................................186
Figure 15-2. Decision Trees for Invasive Device Classification .....................................................187
Figure 15-3. Decision Tree 2 for Invasive Devices .....................................................................188
Figure 15-4. Decision Tree 1 for Active Device Classification .....................................................189
Figure 15-5. Decision Tree 2 for Active Device Classification .....................................................190
Figure 15-6. Decision Tree for Device Classification With Additional Rules. ...............................191
Figure 16-1. Premarket Use of the STED ....................................................................................195
Figure 16-2. Postmarket Use of the STED ................................................................................196
Figure 17-1. Influence of Design Controls on the Design Process ..............................................204
Figure 17-2. Process Validation Decision Tree ............................................................................206
Figure 17-3. Key Activities for Supplier Control .........................................................................207
Figure 18-1. General GHTF Classification System for IVD Medical Devices ...............................213
Figure 18-2. Regulatory Requirements Related to the Device Risk Class ....................................213
Figure 20-1. MDD Decision Tree ..............................................................................................244
Figure 20-2. IVDD Decision Tree ..............................................................................................246
Figure 23-1. Influence of Stakeholders as Drivers of Biosimilars ................................................282
Figure 23-2. Standalone vs. Abbreviated Development Programs ............................................291
Figure 23-3. Regulation in Latin America ..................................................................................307
Figure 23-4. Middle Eastern Market Growth of Pharmaceuticals ................................................308
Figure 24-1. OCABR Decision Flowchart (Extracted from EU Administrative Procedure for Official Control Authority Batch Release—Human Vaccine and Blood Derived Medicinal Products) (June 2016) ..................320
Figure 24-2. Process of Influenza Vaccine Virus Selection and Development ..............................323
Figure 25-1. Overview of Blood Product Manufacturing Process ..............................................334
Figure 25-2. Approaches to be Employed During Blood Product Processing ...............................339
Figure 28-1. Cell Therapy Product Sources and ATMP Manufacturing Process Overview ..........373
Figure 28-2. Indications of Advanced Therapy Trials ..................................................................374
Figure 28-3. ATMP Process Development Framework ...............................................................376
Figure 28-4. Overview ATMP Approval Centers in the US, EU and Japan ..................................377
Figure 28-5. Overview of Challenges Industry and Stakeholders Face in ATMP Development and Commercialization ........................................................................................................................................383
Figure 30-1. US Regulatory Pathways for Marketing Botanical Drug Products ............................405
Figure 30-2. Information Needed in an IND for a Botanical Drug Product ....................................410
Figure 31-1. Overview of the iPSP Process ...................................................................................423
Figure 31-2. Overview of the PIP Procedure ...............................................................................428
Table 25-3. Evidence of Infection Transmission by Human Blood .................................................................336
Table 26-1. Overview of Orphan Drug Framework ...........................................................................................352
Table 27-1. Examples of FDA-Approved Combination Products ......................................................................361
Table 27-2. Combination Product Categories ...................................................................................................363
Table 27-3. Applicable Articles When the Medicinal Product is Ancillary .......................................................368
Table 27-4. Applicable Articles for Devices to Administer Medicinal Products ................................................369
Table 28-1. Approved Autologous Human Cells and Tissue Products in the US, EU and Japan ....................375
Table 28-2. US, EU and Japan Regulatory Framework Overview ....................................................................376
Table 28-3. Overview of EU Regulatory Approach ..........................................................................................378
Table 28-4. Overview of EU Regulatory Approach ..........................................................................................379
Table 28-5. Overview of Applicable US Regulatory Guidelines ....................................................................380
Table 28-6. Overview of Applicable EU Regulatory Guidelines ....................................................................381
Table 28-7. Overview of Applicable Japanese Regulatory Guidelines ............................................................382
Table 30-1. Traditional Herbal or Botanical Product Regulations in Selected Countries ...............................402
Table 30-2. Direct-to-OTC Criteria for BDPs With Only Non-US Experience ................................................407
Table 30-3. Strategic Considerations for Developing a BDP for US Approval ................................................408
Table 30-4. Comparison of BDPs and Conventional Drugs ..............................................................................409
Table 31-1. FDA Pediatric Age Categories for Labeling of Drugs and Biologics .............................................420
Table 31-2. Outline of the initial Pediatric Study Plan (iPSP) ..........................................................................422
Table 31-3. Overview of BPCA and PREA .......................................................................................................424
Table 31-4. Paediatric Regulation—Key Requirements and Incentives ...........................................................426
Table 31-5. Overview of Information Required in a PIP ..................................................................................430